Top

International Urogynecology Journal

Published in:

02-07-2022 | Overactive Bladder | Original Article

How effectively do we apply first-line treatment in overactive bladder?

Authors: Okan Alkis, Aysun Ozlu, Ibrahim Guven Kartal, Mehmet Sevim, Aykut Baser, Bekir Aras

Published in: International Urogynecology Journal | Issue 8/2022

Abstract

Introduction and hypothesis

We aimed to reveal the effectiveness of the combination of behavioral therapy (BT), drug therapy, and pelvic floor muscle training (PFMT) in patients with the diagnosis of overactive bladder (OAB) who did not respond to drug therapy.

Methods

Seventy female patients aged between 18 and 65 years diagnosed with wet-type OAB, who did not respond to drug therapy, were included in our study, which was planned as a prospective randomized controlled trial. The patients were randomly assigned to one of two groups. BT and a combination of anticholinergic + beta3-agonist was implemented in the control group for 12 weeks. BT and PFMT were applied with a combination of anticholinergic + beta3-agonist in the active therapy group for 12 weeks. Post-treatment changes in OAB, ICIQ-SF scores, and frequency and nocturia were compared.

Results

The age and BMI averages of the groups were similar (p>0.01). After the treatment, no significant decrease was observed in OAB scores in the control group (p = 0.06), but a significant decrease was observed in the active therapy group (p<0.01). The mean ICIQ-SF scores and the number of nocturia were found to decrease in both groups after 12 weeks of treatment (p<0.01). There was no significant decrease in frequency in the control group (p = 0.054). It regressed significantly in the active therapy group (p<0.01). After the treatment, 3 of 30 the patients in control group (10%) and 11 of the 32 patients in the active therapy group (34.3%) said that their complaints had regressed and that they were pleased with their current situation. Although after the treatment, 4 patients in the control group were dry (13.3%), 10 patients in the active therapy group were dry (31.25%).

Conclusions

We demonstrated that drug therapy, BT, and PFMT, which are recommended in the first-line treatment of OAB reduce the need for invasive treatments when they are well explained to the patients and combined.

Irwin DE, Kopp ZS, Agatep B, Milsom I, Abrams P. Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. BJU Int. 2011;108:1132–8.CrossRef

Zumrutbas AE, Bozkurt AI, Tas E, Acar CI, Alkis O, et al. Prevalence of lower urinary tract symptoms, overactive bladder and urinary incontinence in western Turkey: results of a population-based survey. Int J Urol. 2014;21(10):1027–33.CrossRef

Abrams P, Artibani W, Cardozo L, Dmochowski R, van Kerrebroeck P, et al. Reviewing the ICS 2002 terminology report: the ongoing debate. Neurourol Urodyn. 2009;28(4):287. https://doi.org/10.1002/nau.20737.CrossRefPubMed

Wein AJ, Kavoussi LR, Partin AV, Peters CA. Campbell-Walsh urology, 11th edition. Elsevier, Amsterdam; 2016.

Smith A, Bevan D, Douglas HR, James D. Management of urinary incontinence in women: summary of updated NICE guidance. BMJ. 2013;347:f5170.CrossRef

Baser A, Eliaçık S, Baykam MM, Tan FU. Clinical manifestations of overactive bladder with migraine as a comorbidity: a prospective cross-sectional study. Int Neurourol J. 2020;24(4):375–81. https://doi.org/10.5213/inj.2040186.093.CrossRefPubMedPubMedCentral

Alkis O, Sevim M, Güven Kartal İ, Baser A, İbrahim İvelik H, Aras B. Comparison of transcutaneous tibial nerve stimulation (TTNS) protocols for women with refractory overactive bladder (OAB): a prospective randomised trial. Int J Clin Pract. 2021;75(9):e14342. https://doi.org/10.1111/ijcp.14342.CrossRefPubMed

Burgio KL, Locher JL, Goode PS, Hardin JM, McDowell BJ, Dombrowski M, et al. Behavioral vs drug treatment for urge urinary incontinence in older women: a randomized controlled trial. JAMA. 1998;280:1995–2000.CrossRef

Rizvi RM, Chughtai NG, Kapadia N. Effects of bladder training and pelvic floor muscle training in female patients with overactive bladder syndrome: a randomized controlled trial. Urol Int. 2018;100:420–7.CrossRef

10.

Bo K, Fernandes ACNL, Duarte TB, Brito LGO, Ferreira CHJ. Is pelvic floor muscle training effective for symptoms of overactive bladder in women? A systematic review. Physiotherapy. 2020;106:65–75.CrossRef

11.

Harding CK, Lapitan MC, Arlandis S, Bø K, Costantini E, Groen J, et al. EAU Guidelines Non-neurogenic Female LUTS. Presented at the EAU Annual Congress Milan 2021. Available at: http://uroweb.org/guidelines/compilations-of-all-guidelines/

12.

Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med. 2010;152:726–32.CrossRef

13.

Özlü A, Yıldız N, Öztekin Ö. Comparison of the efficacy of perineal and intravaginal biofeedback assisted pelvic floor muscle exercises in women with urodynamic stress urinary incontinence. Neurourol Urodyn. 2017;36(8):2132–41. https://doi.org/10.1002/nau.23257.CrossRefPubMed

14.

Tarcan T, Mangır N, Ozgur O, Akbal C. OAB-V8 asırı aktif mesane sorgulama formu validasyon çalışması. Uroloji Bulteni. 2012;21:113–6.

15.

Burgio KL, Kraus SR, Johnson TM 2nd, Markland AD, Vaughan CP, Li P, Redden DT, Goode PS. Effectiveness of combined behavioral and drug therapy for overactive bladder symptoms in men: a randomized clinical trial. JAMA Intern Med. 2020;180(3):411–9. https://doi.org/10.1001/jamainternmed.2019.6398.CrossRefPubMedPubMedCentral

16.

Alkış O, Başer A, Özlülerden Y, Ölçücü MT, Zümrütbaş AE, Aybek Z. Factors facilitating the emergence of overactive bladder in adults with childhood voiding disorder. New J Urol. 2020;15(3):189–93.

17.

Le Berre M, Presse N, Morin M, et al. What do we really know about the role of caffeine on urinary tract symptoms? A scoping review on caffeine consumption and lower urinary tract symptoms in adults. Neurourol Urodyn. 2020;39(5):1217–33. https://doi.org/10.1002/nau.24344.CrossRefPubMed

18.

Erickson BA, Vaughan-Sarrazin M, Liu X, Breyer BN, Kreder KJ, Cram P. Lower urinary tract symptoms and diet quality: findings from the 2000–2001 National Health and Nutrition Examination Survey. Urology. 2012;79(6):1262–7. https://doi.org/10.1016/j.urology.2012.03.004.CrossRefPubMed

19.

Bradley CS, Erickson BA, Messersmith EE, et al. Symptoms of Lower Urinary Tract Dysfunction Research Network (LURN). Evidence of the impact of diet, fluid intake, caffeine, alcohol and tobacco on lower urinary tract symptoms: a systematic review. J Urol. 2017;198(5):1010–20. https://doi.org/10.1016/j.juro.2017.04.097.CrossRefPubMedPubMedCentral

20.

Bø K. Pelvic floor muscle training is effective in treatment of female stress urinary incontinence, but how does it work? Int Urogynecol J. 2004;15(2):76–84.CrossRef

21.

Shafik A, Shafik IA. Overactive bladder inhibition in response to pelvic floor muscle exercises. World J Urol. 2003;20(6):374–7.CrossRef

22.

Bykoviene L, Kubilius R, Aniuliene R, Bartuseviciene E, Bartusevicius A. Pelvic floor muscle training with or without tibial nerve stimulation and lifestyle changes have comparable effects on the overactive bladder. A randomized clinical trial. Urol J. 2018;15(4):186–92.PubMed

23.

Kafri R, Deutscher D, Shames J, Golombp J, Melzer I. Randomized trial of a comparison of rehabilitation or drug therapy for urgency urinary incontinence: 1-year follow-up. Int Urogynecol J. 2013;24(7):1181–9. https://doi.org/10.1007/s00192-012-1992-8.CrossRefPubMed

24.

Kulaksızoğlu H, Akand M, Cakmakci E, Gül M, Seçkin B. Effectiveness of pelvic floor muscle training on symptoms and uroflowmetry parameters in female patients with overactive bladder. Turkish J Med Sci. 2015;45:449–53. https://doi.org/10.3906/sag-1310-95.CrossRef

25.

Scarpero H, Sand PK, Kelleher CJ, Berriman S, Bavendam T, Carlsson M. Long-term safety, tolerability, and efficacy of fesoterodine treatment in men and women with overactive bladder symptoms. Curr Med Res Opin. 2011;27(5):921–30. https://doi.org/10.1185/03007995.2011.559581.CrossRefPubMed

26.

Sand PK, Heesakkers J, Kraus SR, Carlsson M, Guan Z, Berriman S. Long-term safety, tolerability and efficacy of fesoterodine in subjects with overactive bladder symptoms stratified by age: pooled analysis of two open-label extension studies. Drugs Aging. 2012;29(2):119–31. https://doi.org/10.2165/11597970-000000000-00000.CrossRefPubMed

Title: How effectively do we apply first-line treatment in overactive bladder?
Authors: Okan Alkis
Aysun Ozlu
Ibrahim Guven Kartal
Mehmet Sevim
Aykut Baser
Bekir Aras
Publication date: 02-07-2022
Publisher: Springer International Publishing
Keyword: Overactive Bladder
Published in: International Urogynecology Journal / Issue 8/2022
Print ISSN: 0937-3462
Electronic ISSN: 1433-3023
DOI: https://doi.org/10.1007/s00192-022-05279-2

At a glance: The STEP trials

Springer Medicine

How effectively do we apply first-line treatment in overactive bladder?

Abstract

Introduction and hypothesis

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Introduction and hypothesis

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 8/2022

Evaluating tissue-engineered repair material for pelvic floor dysfunction: a comparison of in vivo response to meshes implanted in rats

Covert postpartum urinary retention: causes and consequences (PAREZ study)

Mechanical stress influences the morphology and function of human uterosacral ligament fibroblasts and activates the p38 MAPK pathway

Predictors of postoperative complications from stress urinary incontinence procedures: a NSQIP database study

Associations between metabolic syndrome and female stress urinary incontinence: a meta-analysis

Correlation between symptoms and imaging findings including pelvic floor ultrasound to improve the symptom-based diagnosis of female urethral diverticulum (CHECK-UD study)